Smartphone based therapy management is the future of diabetes treatment. Combine the mylife YpsoPump insulin pump, the mylife CamAPS FX mobile application and the Dexcom G6 or FreeStyle Libre 3 Continuous Glucose Monitoring (CGM) System for an automated insulin delivery system managed directly from your smartphone. The integration of automated insulin delivery into the mylife YpsoPump system portfolio allows you time away from your diabetes and more freedom to do what you love doing.

How mylife Loop works

For automated insulin delivery with the mylife YpsoPump you need the mylife CamAPS FX app and the Dexcom G6 or FreeStyle Libre 3 CGM. Connect the mylife CamAPS FX app to the insulin pump and sensor. The sensor sends glucose data every minute (FreeStyle Libre 3) or every five minutes (Dexcom G6) to the mylife CamAPS FX app. Based on those readings, the app adjusts insulin delivery on the insulin pump every eight to twelve minutes to prevent low and high glucose levels.

The mylife CamAPS FX app is personalised and adaptive; it constantly learns and quickly adapts to ever changing insulin needs. It adjusts to diurnal and day-to-day variations in insulin requirements and compensates for over and under-dosing of the meal bolus. For increased privacy and convenience, you are able to deliver a meal bolus directly from your smartphone.

The mylife CamAPS FX app is approved for people with type 1 diabetes aged one year and over, including pregnant women. Approved for people with type 1 diabetes aged two years and over when used in combination with Dexcom G6 or aged four years and over when used in combination with FreeStyle Libre 3.

mylife Loop - CamAPS Video

mylife CamAPS FX How does it learn?

CamAPS FX - Learning

Prof. Roman Hovorka, developer of the mylife CamAPS FX app, explains how the mylife CamAPS FX algorithm learns.

The learning takes place on three levels:

Level 1
Overall learning: This learning is based on the body’s overall insulin need; the insulin needed on average and during the day.

Level 2
Diurnal learning (over 24 hours): This learning is based on how much insulin is needed for a specific hour in a day. 

Level 3
Post-meal learning: When the user delivers a meal bolus, the system will observe whether the insulin amount was appropriate. If a user constantly over or underestimates carbohydrates, the system will start to adjust insulin delivery post-meal.

All these learnings are occurring continuously.

Specifications mylife CamAPS FX

Screen overview

Navigation (Home screen)
Home screen
Detailed graph (to view the detailed graph rotate the home screen into landscape configuration or tap the "screen rotation" icon).

Main features

Age limit: The mylife CamAPS FX app is approved for people with type 1 diabetes aged one year and over, including pregnant women. Approved for people with type 1 diabetes aged two years and over when used in combination with Dexcom G6 or aged four years and over when used in combination with FreeStyle Libre 3.
Phone compatibility: Android smartphones compatible with Dexcom: www.dexcom.com/compatibility

Android smartphones compatible with FreeStyle Libre 3: https://www.diabetescare.abbott/support/manuals.html (see document “Mobile Device & OS Compatibility”). If using a FreeStyle Libre 3 sensor, please ensure you have an Android smart device with NFC (near field communication).

For Companion remote monitoring only: Android smartphones running OS 8 and above.
Compatible CGM (Continuous Glucose Monitoring) sensors: Dexcom G6: factory calibrated, blood glucose tests only needed in exceptional cases (consult the Dexcom G6 Instructions for Use).
FreeStyle Libre 3: no calibration neccessary, blood glucose tests only needed in exceptional cases (consult the FreeStyle Libre 3 Instructions for Use).
Total daily dose (TDD) and weight range: 5-350 units/day total daily dose (TDD)
10-300 kg weight
Algorithm: Treat to target.
Predictive control: the algorithm calculates the insulin requirement for the next 2.5-4 hours.
Adaptive model: insulin delivery is adjusted every 8-12 minutes.
Learning: Continually adjusting insulin delivery every 8-12 minutes based on CGM glucose data received every minute (FreeStyle Libre 3) or every 5 minutes (Dexcom G6). Learning from previous insulin delivery and meal bolus information to adapt to diurnal, day-to-day as well as post-meal insulin needs.
Glucose target: Default target: 5.8 mmol/L (104 mg/dL)
Customisable personal target: 4.4-11.0 mmol/L (80-198 mg/dL)
Data sharing: Yes, via:
mylife CamAPS FX app on smartphone: generation and export of PDF reports including glucose statistics, insulin statistics, "Auto mode" and alert statistics, information about settings and weekly overviews. Internet connectivity is required to generate PDF reports.

Glooko: automated data upload from the mylife CamAPS FX app to the Glooko platform to share data with healthcare professionals. Internet connectivity is required to share data with Glooko.
Remote monitoring: Yes, via:
Companion remote monitoring: the mylife CamAPS FX app allows user's data to be shared with up to 10 "companions". Remote monitoring is integrated into the app and therefore both, user and "companion", use the mylife CamAPS FX app. CGM data, insulin data and other data as well as alerts are mirrored in the "companion's" mylife CamAPS FX app. Internet connectivity is required to share data with "companions".

SMS based remote monitoring: the mylife CamAPS FX app supports SMS based remote monitoring. All app generated alarms and alerts will be sent via SMS message to up to 5 "followers". A SIM card is required to send SMS messages to "followers".

Please note that it is possible to use the Companion remote monitoring and SMS based remote monitoring at the same time.
Discrete bolusing: Yes, via mylife CamAPS FX app on smartphone.
Bolus calculator: Yes, via mylife CamAPS FX app on smartphone.
Additional features: “Boost” and “Ease-off” modes
Slowly absorbed meal function

Clinical benefits and other user advantages

The only automated insulin delivery algorithm approved for ages one year and over*

There is an overall acceptance of the closed-loop approach across all age groups: pre-schoolers1Ware J. et al.: Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes. N Engl J Med. 2022 Jan;386(3):209-219. DOI: 10.1056/NEJMoa2111673, children2Barnard K. D. et al.: Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy. J Diabetes Sci Technol. 2017 Nov;11(6):1080-1088. DOI: 10.1177/1932296817702656,3Tauschmann M. et al.: Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet. 2018 Oct;392(10155):1321-1329. DOI: 10.1016/S0140-6736(18)31947-0,4Ware J. et al.: Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. The Lancet Digital Health. 2022 Apr;4(4):e245-e255. DOI:10.1016/ S2589-7500(22)00020-6, adolescents2Barnard K. D. et al.: Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy. J Diabetes Sci Technol. 2017 Nov;11(6):1080-1088. DOI: 10.1177/1932296817702656,3Tauschmann M. et al.: Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet. 2018 Oct;392(10155):1321-1329. DOI: 10.1016/S0140-6736(18)31947-0,4Ware J. et al.: Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. The Lancet Digital Health. 2022 Apr;4(4):e245-e255. DOI:10.1016/ S2589-7500(22)00020-6, adults2Barnard K. D. et al.: Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy. J Diabetes Sci Technol. 2017 Nov;11(6):1080-1088. DOI: 10.1177/1932296817702656,3Tauschmann M. et al.: Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet. 2018 Oct;392(10155):1321-1329. DOI: 10.1016/S0140-6736(18)31947-0 and older adults5Boughton C. K. et al.: Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study. Lancet Healthy Longev. 2022 Mar;3(3):e135–e142. DOI: 10.1016/S2666-7568(22)00005-8. Reduced burden of diabetes and improved quality of life in children, adolescents and adults were observed2Barnard K. D. et al.: Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy. J Diabetes Sci Technol. 2017 Nov;11(6):1080-1088. DOI: 10.1177/1932296817702656. Psychosocial benefits reported by parents and caregivers included improved sleep, improved quality of life, and reduced burden of diabetes6Musolino G. et al.: Reduced burden of diabetes and improved quality of life: Experiences from unrestricted day-and-night hybrid closed-loop use in very young children with type 1 diabetes. Pediatr Diabetes. 2019 Sep;20(6):794-799. DOI: 10.1111/pedi.12872. Closed-loop is also a safe and clinically important treatment option for older adults5Boughton C. K. et al.: Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study. Lancet Healthy Longev. 2022 Mar;3(3):e135–e142. DOI: 10.1016/S2666-7568(22)00005-8.

The use of CamAPS FX in young children aged 1 to 7 years documented clinically and statistically significant reduction of HbA1c by 0.4%, and an increase in time in target glucose range by 9% without increasing time in hypoglycaemia below 3.9 mmol/L (70 mg/dL)1Ware J. et al.: Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes. N Engl J Med. 2022 Jan;386(3):209-219. DOI: 10.1056/NEJMoa2111673.

The use of the CamAPS FX control algorithm in people aged 6 years and older including adults resulted in reduction of HbA1c by 0.4%, increased time in target glucose range by 11%, and reduced time in hypoglycaemia below 3.9 mmol/L (70 mg/dL) by 0.8%3Tauschmann M. et al.: Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet. 2018 Oct;392(10155):1321-1329. DOI: 10.1016/S0140-6736(18)31947-0. This signifies the importance and the ability of the CamAPS FX control algorithm to achieve desirable glucose control safely.

The comparator in both studies was sensor augmented pump therapy applying identical insulin pump and identical glucose sensor but not using the control algorithm.

* Approved for people with type 1 diabetes aged two years and over when used in combination with Dexcom G6 or aged four years and over when used in combination with FreeStyle Libre 3.

Read about Emmie’s experience with the automated insulin delivery system mylife Loop .

Parents and caregivers can have peace of mind thanks to remote monitoring

Control and monitoring of blood sugar, especially overnight, is a relief and leads to a better night’s sleep. The burden of diabetes for parents and caregivers is reduced significantly and they feel less worried about their child’s glucose control. In general, users are able to spend less time managing their diabetes.6Musolino G. et al.: Reduced burden of diabetes and improved quality of life: Experiences from unrestricted day-and-night hybrid closed-loop use in very young children with type 1 diabetes. Pediatr Diabetes. 2019 Sep;20(6):794-799. DOI: 10.1111/pedi.12872

Improved glucose control during pregnancy

Closed-loop insulin delivery was associated with comparable glucose control and significantly less hypoglycaemia than sensor augmented pump therapy. Moreover, closed-loop insulin delivery was reported as safe and could effectively control glucose levels in a broad range of pregnant women with type 1 diabetes.7Stewart Z. A. et al.: Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women With Type 1 Diabetes: A Randomized Controlled Crossover Trial. Diabetes Care. 2018 Jul;41(7):1391-1399. DOI: 10.2337/dc17-2534

Closed-loop performed well during labour and delivery. The system adapted quickly to the rapid change in insulin requirements after delivery, with women spending over 80% time in target glucose range in the immediate postpartum period.8Stewart Z. A. et al.: Adaptability of Closed Loop During Labor, Delivery, and Postpartum: A Secondary Analysis of Data from Two Randomized Crossover Trials in Type 1 Diabetes Pregnancy. Diabetes Technol Ther. 2018 Jul; 20(7):501-505. DOI: 10.1089/dia.2018.0060

Improved quality of life thanks to an adaptive and self-learning automated insulin delivery system

The mylife CamAPS FX app constantly learns and quickly adapts to ever changing insulin needs. It adjusts to diurnal and day-to-day variations in insulin requirements and compensates for over and under-dosing of meal bolus. If a user consistently over or underestimates carbohydrates, the algorithm adjusts insulin delivery accordingly, to prevent low and high glucose levels. This enables safe and efficient use in all life circumstances2Barnard K. D. et al.: Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy. J Diabetes Sci Technol. 2017 Nov;11(6):1080-1088. DOI: 10.1177/1932296817702656.

Full flexibility with "Boost" and "Ease-off" modes

Are you planning to exercise? Is it hot outside? The "Ease-off" mode reduces insulin delivery depending on glucose levels, raises the glucose target temporarily and stops insulin delivery if your glucose level is predicted to fall below target. On the flip side, you are also able to "Boost" to make the algorithm more responsive and to increase insulin delivery by ~35%. This can come in handy in instances like if you happen to miss a bolus or your period is due. Once glucose reaches your target, the "Boost" mode will not push glucose lower than your target.

Personalised diabetes management

Do you need to go higher in the morning and lower in the afternoon with your glucose levels? You can adjust your own personal target between 4.4-11.0 mmol/L (80-198 mg/dL) in 30 minute segments. Furthermore, with the slowly absorbed meal function, the algorithm will deliver extra insulin over 3-4 hours, depending on glucose levels.

What mylife Loop users say

I can’t imagine having such an active lifestyle without the mylife Loop. I have three children and enjoy regular exercise. I am so grateful I now have more time to enjoy the beautiful things in life.

Kathi, diagnosis at 21

I love how the app algorithm started to recognise the patterns in my blood sugars and works to keep me in range. But the best thing for me was finally getting a full night’s sleep.

Oisin, diagnosis at 9

Having more stable blood glucose and better time in range makes everyday life easier.

Susanne, diagnosis at 38

Make the first step – switch to auto mode

Book a demo now and our experts will happily walk you through the automated insulin delivery system mylife Loop.

Note:

We only use the data you provide us with on this form for the above-mentioned purpose. We do not save the data on this web server. For more information on the collection and processing of your data, please refer to our Privacy Policy.

Please calculate 8 plus 8.

* mandatory field

Easy start in just five steps

Step 1

Complete the mylife CamAPS FX online training, or ask your healthcare professional for training.

Step 2

Download the mylife CamAPS FX app and set up your account.

Step 3

Connect the app to your mylife YpsoPump.

Step 4

Connect the app to your CGM.

Step 5

Complete the bolus calculator settings and configure and synchronise your CGM sensor.

Online training

CamAPS FX training portal

Complete the mylife CamAPS FX online training, or ask your healthcare professional for training, and you are ready to start using the system as a certified mylife CamAPS FX user. Note that you require a version of the mylife YpsoPump that is compatible with the mylife CamAPS FX app and a connected Dexcom G6 or FreeStyle Libre 3 CGM to use mylife Loop.

Download

Download the mylife CamAPS FX app from the Google Play Store.

Available on Android phones. iOS will follow.

Did you know?

The mylife CamAPS FX app can also be used in demo mode and connected to a virtual insulin pump and a virtual CGM. Try it out. Please note: A virtual CGM is available for use with virtual pump only. It cannot be used in combination with a real pump. A virtual CGM should be used for demonstration and training purposes only. No alerts and alarms will be sounded. Not all CGM features will be available.

Dexcom G6

Dexcom G6

Discover Dexcom G6. Visit the sensor information page.

FreeStyle Libre 3

Freestyle Libre 3

Discover Freestyle Libre 3. Visit the sensor information page.

Referenced clinical studies

1 Ware J. et al.: Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes.
N Engl J Med. 2022 Jan;386(3):209-219. DOI: 10.1056/NEJMoa2111673

2 Barnard K. D. et al.: Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy.
J Diabetes Sci Technol. 2017 Nov;11(6):1080-1088. DOI: 10.1177/1932296817702656

3 Tauschmann M. et al.: Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet. 2018 Oct;392(10155):1321-1329. DOI: 10.1016/S0140-6736(18)31947-0

4 Ware J. et al.: Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. The Lancet Digital Health. 2022 Apr;4(4):e245-e255. DOI:10.1016/ S2589-7500(22)00020-6

5 Boughton C. K. et al.: Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study. Lancet Healthy Longev. 2022 Mar;3(3):e135–e142. DOI: 10.1016/S2666-7568(22)00005-8

6 Musolino G. et al.: Reduced burden of diabetes and improved quality of life: Experiences from unrestricted day-and-night hybrid closed-loop use in very young children with type 1 diabetes. Pediatr Diabetes. 2019 Sep;20(6):794-799. DOI: 10.1111/pedi.12872

7 Stewart Z. A. et al.: Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women With Type 1 Diabetes: A Randomized Controlled Crossover Trial. Diabetes Care. 2018 Jul;41(7):1391-1399. DOI: 10.2337/dc17-2534

8 Stewart Z. A. et al.: Adaptability of Closed Loop During Labor, Delivery, and Postpartum: A Secondary Analysis of Data from Two Randomized Crossover Trials in Type 1 Diabetes Pregnancy. Diabetes Technol Ther. 2018 Jul; 20(7):501-505. DOI: 10.1089/dia.2018.0060

 

Disclaimer:

The product images are for illustrative purposes only.

mylife and YpsoPump are registred trademarks of Ypsomed AG.

CamAPS is a registered trademark of CamDiab Ltd.

Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. in the United States and/or other countries.

The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission.

The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks by Ypsomed is under license.

Other trademarks and trade names are those of their respective owners.

mylife Loop: The innovation described is available in selected countries and expanding to further countries soon. Expansion is contingent upon local regulatory approval.

For safety information on mentioned products, see mylife-diabetescare.com/safety